China’s VivaVision Biotech Inc. has announced a collaboration agreement with Israel-based Everads Therapy Ltd to develop safer, more effective, and lasting novel therapies targeting retinal diseases. The partnership aims to leverage the strengths of both companies to advance innovative treatments for these conditions.
Collaboration Details
The collaboration is designed to safely and accurately deliver highly active small molecule therapeutic drugs designed by VivaVision to the superior choroidal cavity of patients through Everads’ choroidal injection device and professional technology. VivaVision will design a small molecule with high drug activity that is more suitable for suprachoroidal injection against the target of retinal disease.
Suprachoroidal Injection Technology
Suprachoroidal injection is a potential drug delivery technology targeting ocular fundus diseases. The suprachoroidal cavity (SCS) refers to the potential space between the choroid and sclera. When injected into the SCS, therapeutic drugs can be accurately delivered to the site of the disease (choroid and retina), playing a targeted role in the treatment of various fundus diseases.
Clinical Validation and Market Potential
Clinical data of the drug delivery technology and the first such drug approved by the US FDA have verified the therapeutic advantages and market potential of suprachoroidal administration. This validation underscores the potential of the technology to significantly improve outcomes for patients with retinal diseases.
Future Outlook
The collaboration between VivaVision Biotech and Everads Therapy highlights the commitment of both companies to advancing innovative treatments for retinal diseases. By combining VivaVision’s expertise in small molecule drug design with Everads’ advanced delivery technology, the partnership is poised to make a meaningful impact on patient care. The development of safer and more effective therapies could address significant unmet needs in ophthalmology.-Fineline Info & Tech
